Clinical trial / 2020
Long-term vitamin D3 supplementation did not reduce the risk of depression or improve mood scores in adults aged 50 or older.
In the VITAL-DEP randomized clinical trial, 18,353 participants aged 50 years or older were assigned to vitamin D3 (2000 IU/d) or placebo for a median duration of 5.3 years. Risk of depression or clinically relevant depressive symptoms did not significantly differ between the vitamin D3 group (12.9/1000 person-years) and placebo (13.3/1000 person-years; HR 0.97, 95% CI 0.87 to 1.09; P = .62). There were also no significant differences in depression incidence, recurrence, or change in PHQ-8 mood scores over time (mean difference 0.01 points, 95% CI -0.04 to 0.05 points).
- Study type
- Randomized controlled trial (2 x 2 factorial)
- Who was studied
- 18,353 adults aged 50 years or older in the US
- What was measured
- Risk of depression or clinically relevant depressive symptoms and change in PHQ-8 mood scores
THE PAPER
Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.
Okereke OI, Reynolds CF, Mischoulon D, Chang G, Vyas CM, Cook NR, Weinberg A, Bubes V, Copeland T, Friedenberg G, Lee IM, Buring JE, Manson JE. JAMA, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.